Introduction
============

Breast cancer is the most frequently diagnosed cancer and the leading cause of death from cancer in women. The mainstay treatment of early breast cancer is surgery. Previously, mastectomy was the standard operation, but recently breast-conserving surgery (BCS; wide local excision or lumpectomy) has been becoming one of the primary surgical treatments. Several studies that compared the outcomes of BCS followed by whole-breast irradiation and mastectomy showed that the two operation techniques were equivalent with regard to long-term survival[@b1-bctt-8-047]--[@b4-bctt-8-047] if there were no contraindications, and thus should be the treatment of choice for women with relatively small breast cancers.[@b1-bctt-8-047] Local recurrence after treatment with BCS occurs in about 10%--20% of patients for early invasive breast cancer.[@b5-bctt-8-047] Studies reporting recurrence factors after BCS[@b5-bctt-8-047]--[@b7-bctt-8-047] have come from the US and Europe, but seldom from Asia. Chiang Mai University Hospital had not collected data regarding BCS, so the purpose of this study was to collect data of breast cancer profiles and factors affecting local recurrence and distant metastasis after BCS.

Materials and methods
=====================

This study was a retrospective review from digital medical records of Chiang Mai University Hospital. The study protocols were approved by the Chiang Mai University Institutional Ethical Committee, Thailand. Patient consent was not required in this retrospective study according to the ethics committee of the Chiang Mai University hospital. The data collected included the following: patients diagnosed with invasive breast cancer without documentation for distant metastasis at the first diagnosis; and with regard to treatment characteristics and follow-up, patients who had undergone treatment with BCS plus axillary lymph-node (ALN) evaluation that included sentinel lymph-node (SLN) and axillary lymph-node dissection (ALND) in Chiang Mai University Hospital from April 9, 2001 until December 25, 2011.

A total of 185 patients treated with BCS were included in this study. Collected data analyzed included age, menopausal status, clinical T (tumor), clinical N (node involvement), LN (lymph-node) operation that included SLN and ALND, number of positive LNs, histologic type, lymphovascular invasion, margin status, histologic grade, nuclear grade, hormonal status, HER2 status, chemotherapy, and antihormonal treatment. Patients were followed up every 3 months at the Head, Neck, and Breast Unit, Outpatient Department by physical examination. Chest imaging and mammography were performed annually. The patients were divided into two groups: recurrence including locoregional and distant metastases, and the nonrecurrence group ([Figure 1](#f1-bctt-8-047){ref-type="fig"}).

Statistical analysis
--------------------

Statistical analysis was done with commercial statistical software (Stata 11.0; StataCorp LP, College Station, TX, USA). We report descriptive categorical data with percentage and analysis with Fisher's exact test, descriptive numerical data with mean and standard deviation, and analysis with Student's *t*-test. *P*-values less than 0.05 were considered statistically significant. Survival was calculated by the Kaplan--Meier method.

Results
=======

General patient characteristics
-------------------------------

A total of 185 female patients were treated with BCS. The median age at diagnosis of invasive breast cancer was 46.83 years (range 45.37--48.29 years). The nonrecurrence group comprised 166 patients, and the recurrence group consisted of 19 patients (10.27%). The median age in the nonrecurrence group was 47.48 years and in the recurrence group 41.11 years (*P*\<0.01). In premenopausal status patients, we found that the recurrence rate was 10.27% (19 patients), but there was no recurrence in the menopausal status patients (*P*=0.047) ([Table 1](#t1-bctt-8-047){ref-type="table"}).

Clinical T, N, and tumor histologic types
-----------------------------------------

At the time of diagnosis the majority of clinical T patients in the nonrecurrence group were clinical T1, as were the patients in recurrence group. Clinical N patients were N0 in both nonrecurrence and recurrence groups (75.14% and 7.57%, respectively). Clinical N was N0 in both groups (75.14% and 7.57% in nonrecurrence and recurrence, respectively). The histologic type was invasive ductal carcinoma in both groups (167 patients \[90.27%\]) ([Table 2](#t2-bctt-8-047){ref-type="table"}). There was no statistical difference in clinical T and clinical N between the recurrence and nonrecurrence groups (*P*=0.219 and 0.227, respectively) ([Table 3](#t3-bctt-8-047){ref-type="table"}).

Nuclear and histologic grade
----------------------------

The majority of nuclear grade 2 occurred in the nonrecurrence group (40%), and nuclear grade 3 occurred more frequently in the recurrence group (5.41%). No statistical difference was determined for nuclear grade between the recurrence and nonrecurrence groups (*P*=0.458).

Histologic grade 2 was primarily in the nonrecurrence group (43.24%), and histologic grade 3 occurred more frequently in the recurrence group 4.86%). There was no statistical difference in nuclear grade between the recurrence and nonrecurrence groups (*P*=0.611) ([Table 3](#t3-bctt-8-047){ref-type="table"}).

Hormonal and HER2 status
------------------------

Hormonal expression was divided into estrogen receptor (ER) and progesterone receptor (PR). In ER, most patients in the nonrecurrence group were ER 3+, while ER was not expressed in the recurrence group. There was a significant statistical difference in ER expression between the two groups. While consideration of PR in the nonrecurrence group revealed that patients who had PR 3+ and negative PR were similar in number (61 and 68 patients), in the recurrence group we found that patients with negative PR had a higher recurrence rate, with statistical significance. There was HER2 overexpression in 76 patients (41.08%) and nonexpression in 99 patients (58.92%). No statistical difference in HER2 status was shown between the recurrence and nonrecurrence groups (*P*=0.224). Triple-negative patients trended toward more recurrence without a statistical difference (*P*=0.337) ([Table 3](#t3-bctt-8-047){ref-type="table"}).

Lymphovascular invasion
-----------------------

There was no statistical difference between the groups (*P*=0.583) ([Table 3](#t3-bctt-8-047){ref-type="table"}).

Lymph-node operation
--------------------

We have performed SLN biopsy since 1999. A total of 96 of the BCS patients had undergone SLN. Seven SLN-positive patients were divided into six patients in the nonrecurrence group and one patient in the recurrence group and further ALND. ALND was performed in 80 patients. No statistical difference was found in LN operations between the two groups ([Table 4](#t4-bctt-8-047){ref-type="table"}). In the subgroup analysis of positive LNs, we found that having more than two positive LNs trended toward recurrence (*P*=0.066) ([Table 4](#t4-bctt-8-047){ref-type="table"}).

Margin status
-------------

A positive margin was found in 7.14% of overall patients who refused reexcision, and a negative margin was obtained in 92.86%. No statistical difference was determined between the recurrence and nonrecurrence groups (*P*=0.63) ([Table 4](#t4-bctt-8-047){ref-type="table"}).

Chemotherapy treatment
----------------------

We analyzed groups divided into neoadjuvant chemotherapy and adjuvant chemotherapy. Neoadjuvant chemotherapy was administered 11.11% of the time in the recurrence group and 7.88% of the time in the nonrecurrence group. In the recurrence group, adjuvant chemotherapy was received 88.89% of the time, and in the non-recurrence group 92.12% of the time. There were no statistical differences regarding chemotherapy treatments ([Table 5](#t5-bctt-8-047){ref-type="table"}).

Antihormonal treatment
----------------------

In the nonrecurrence group, 84 of the patients received tamoxifen. Most of the recurrence group did not receive antihormonal treatment, due to their non-hormone-expression status, with a statistically significant difference in both groups (*P*=0.011) ([Table 5](#t5-bctt-8-047){ref-type="table"}).

Length of follow-up
-------------------

From Kaplan--Meier analysis, we found that the recurrence rate after BCS decreased after 90 months (7.5 years) from the date of operation ([Figure 2](#f2-bctt-8-047){ref-type="fig"}). Premenopausal women were the only group with recurrence.

Discussion
==========

In this study, our purpose was to find factors that affected recurrence (locoregional and distant metastasis) after BCS in patients who were diagnosed with invasive breast cancer in Chiang Mai University Hospital. The local recurrence rate after BCS ranges from 10% to 20%,[@b5-bctt-8-047] and from our study 10.27% included local and distant metastasis. Univariate analyses indicated that younger age and premenopausal status were risk factors for recurrence. This result was similar to previous studies.[@b6-bctt-8-047]--[@b9-bctt-8-047] With regard to the tumor size, our study was in contrast to the results of Martínez-Ramos et al, who found that patients who received BCS with a tumor size more than 2 cm had a higher local recurrence rate.[@b10-bctt-8-047] None of the menopausal women had a recurrence in this study. Estrogen-overexpression patients demonstrated less recurrence than patients who had negative or minimal ER expression, with significant statistical difference, which was the same as other studies.[@b5-bctt-8-047],[@b11-bctt-8-047] The luminal A subtype locoregional recurrence occurred less than other subtypes. Consequently, patients who received antihormonal treatment had less recurrence than the nontreatment group. One reason that patients who had positive ER had less recurrence could be the benefit of endocrine therapy, which has been shown in many studies to reduce the risk of recurrence significantly.[@b12-bctt-8-047]--[@b14-bctt-8-047] Several studies have reported that the locoregional recurrence rate is higher if there is LN metastasis, positive margin status and lymphovascular invasion,[@b5-bctt-8-047],[@b15-bctt-8-047]--[@b18-bctt-8-047] but this is opposite to our results, because there was no effect on recurrence. Conversely, HER2 overexpression is one of the risk factors for breast cancer recurrence,[@b19-bctt-8-047]--[@b21-bctt-8-047] but in this study HER2 did not affect recurrence. This result may have been due to fewer patients developing recurrence and needing longer follow-up, which may in itself have been a result of too few patients being enrolled for there to be a statistically significant difference.

Nineteen patients had a recurrence after BCS, with nine patients having locoregional recurrence and ten patients with distant metastasis. Five patients died within 2 years after diagnosis of distant metastasis. Pulmonary metastasis was found in three of five patients who died from breast cancer. Four in ten patients had more than one site of metastasis (one patient developed lung, liver, and bone metastasis, and three patients developed lung and bone metastasis). The most common site of distant metastasis was bone (seven patients). Finally, the recurrence rate decreased after 90 months (7.5 years) of follow-up from the date of BCS ([Figure 2](#f2-bctt-8-047){ref-type="fig"}).

Several potential limitations to this study included the small number of patients in both groups, and some data were missed due to the retrospective review. Previously, our hospital did not report about Ki-67 in pathological reports so in this study Ki-67 was not included in the statistical analysis.

Conclusion
==========

The recurrence rate at our institute was 10.27%. Factors that affected recurrence after BCS included young age, premenopausal status, nonexpression of ER and PR, and patients who did not receive antihormonal treatment. The recurrence rate was also higher in the first 90 months after the operation.
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###### 

Patient characteristics

                                Recurrence (n)         Nonrecurrence (n)      *P*-value
  ----------------------------- ---------------------- ---------------------- -----------
  Patients (n=185)              19 (10.27%)            166 (89.73%)           
   Average age, years (range)   41.11 (36.98--45.23)   47.48 (45.94--49.02)   0.0085
  Menopausal status                                                           0.047
   Premenopausal                19 (10.27%)            137 (74.1%)            
   Menopausal                   0                      29 (15.68%)            

**Abbreviation:** SD, standard deviation.

###### 

Histologic type of invasive breast cancer

  -----------------------------------------------------------------
                         Recurrence\   Nonrecurrence\   *P*-value
                         (n)           (n)              
  ---------------------- ------------- ---------------- -----------
  Histologic type                                       0.323

   Ductal carcinoma      17 (9.19%)    149 (80.54%)     

   Lobular carcinoma     0             4 (2.16%)        

   Papillary carcinoma   1 (0.54%)     5 (2.70%)        

   Medullary carcinoma   0             3 (1.62%)        

   Mucinous carcinoma    0             4 (2.16%)        

   Tubular carcinoma     0             1 (0.54%)        

   Neuroendocrine        1 (0.54%)     0                
  -----------------------------------------------------------------

###### 

Clinicopathologic characteristics

                     Recurrence (n)   Nonrecurrence (n)   *P*-value
  ------------------ ---------------- ------------------- -----------
  Clinical T                                              0.219
   T1                18 (9.73%)       162 (87.57%)        
   T2                0                3 (1.62%)           
   T3                1 (0.54%)        1 (0.54%)           
  Clinical N                                              0.227
   N0                14 (7.57%)       139 (73.13%)        
   N1                4 (2.16%)        23 (12.43%)         
   N2                0                3 (1.62%)           
   N3                1 (0.54)         1 (0.54%)           
  Histologic grade                                        0.611
   1                 0                8 (4.32%)           
   2                 8 (4.32%)        80 (43.24%)         
   3                 9 (4.86%)        63 (34.05%)         
  Nuclear grade                                           0.458
   1                 0                12 (6.49%)          
   2                 8 (4.32%)        74 (40%)            
   3                 10 (5.41%)       66 (35.68%)         
  ER status                                               0.001
   0                 10 (5.62%)       53 (29.78%)         
   1+                3 (1.69%)        11 (6.18%)          
   2+                4 (2.25%)        11 (6.18%)          
   3+                2 (1.12%)        84 (47.19%)         
  PR status                                               0.003
   0                 11 (6.18%)       68 (38.20%)         
   1+                2 (1.12%)        18 (10.11%)         
   2+                5 (2.81%)        12 (6.74%)          
   3+                1 (0.56%)        61 (34.27%)         
  HER2 status                                             0.224
   Negative          10 (5.41%)       89 (48.11%)         
   Equivocal (2+)    3 (1.62%)        35 (18.92%)         
   3+                6 (3.24%)        32 (17.3%)          
  Triple-negative                                         0.337
   No                126 (73.68%)     13 (7.60%)          
   Yes               27 (15.79%)      5 (2.92%)           
  LVI                                                     0.583
   Negative          93 (54.07%)      11 (6.39%)          
   Positive          61 (35.47%)      7 (4.07%)           

**Abbreviations:** LVI, lymphovascular invasion; T, tumor; N, node involvement; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

###### 

Lymph-node operation and margin status

  ---------------------------------------------------------------------
                             Recurrence\   Nonrecurrence\   *P*-value
                             (n)           (n)              
  -------------------------- ------------- ---------------- -----------
  Lymph-node operation                                      0.107

   SLN                       13 (7.10%)    83 (45.36%)      

   ALND                      4 (2.19%)     76 (41.53%)      

   SLN-positive, then ALND   1 (0.55%)     6 (3.28%)        

  Number of positive LNs                                    0.066

   LN-positive 0--2          13 (7.10%)    146 (79.78%)     

   LN-positive ≥3            5 (2.73%)     19 (10.38%)      

  Margin status                                             0.63

   Negative                  17 (9.34%)    152 (83.52%)     

   Positive                  2 (1.1%)      11 (6.04%)       
  ---------------------------------------------------------------------

**Abbreviations:** LN, lymph-node; SLN, sentinel LN; ALND, axillary LN dissection.

###### 

Type of chemotherapy and antihormonal treatment

  -----------------------------------------------------------------
                         Recurrence\   Nonrecurrence\   *P*-value
                         (n)           (n)              
  ---------------------- ------------- ---------------- -----------
  Type of chemotherapy                                  0.646

   Neoadjuvant           2 (1.09%)     13 (7.10%)       

   Adjuvant              16 (8.74%)    152 (83.06%)     

  Trastuzumab                                           0.252

   Yes                   2 (1.10%)     9 (4.97%)        

   No                    14 (7.73%)    156 (86.19%)     

  Hormonal treatment                                    0.011

   None                  12 (6.59%)    56 (30.77%)      

   Tamoxifen             5 (2.75%)     84 (46.15%)      

   Aromatase inhibitor   0             22 (12.09%)      

   Switching             1 (0.55%)     2 (1.10%)        
  -----------------------------------------------------------------
